Concentration of credit risk and current expected credit losses (Tables)

6 Months Ended

Jun. 30, 2020

Concentration of credit risk and current expected credit losses

Schedule of concentration of credit risk related to specialty pharmacy customers

In November 2011, we began commercialization and distribution of JAKAFI and in April 2020, we began commercialization and distribution of PEMAZYRE to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI and PEMAZYRE product revenues is as follows:

	Percentage of Total Net				Percentage of Total Net
	Product Revenues for the				Product Revenues for the
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Customer A	20	%	20	%	19	%	19	%
Customer B	14	%	13	%	13	%	14	%
Customer C	16	%	16	%	17	%	16	%
Customer D	11	%	11	%	11	%	12	%